Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 74 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 5-aminosalicylic acid Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine

NCT01418365
View directory record Official record
Conditions
Healthy
Interventions
Metronidazole + MMX Mesalazine/mesalamine placebo, Metronidazole + MMX Mesalazine/mesalamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

NCT01532648
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Budesonide MMX®, Placebo, 5-ASA
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
39
States / cities
Anaheim, California • Lakewood, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 2, 2026, 3:23 PM EDT
Terminated Phase 3 Interventional Results available

A Study With Pentasa in Patients With Active Crohn's Disease

NCT00862121
View directory record Official record
Conditions
Crohn´s Disease
Interventions
Pentasa, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
San Diego, California • Clearwater, Florida • John's Creek, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 3 Interventional

A Double Blind Study for the Treatment of Acute Ulcerative Colitis

NCT00350415
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalamine
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 75 Years
Enrollment
772 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
78
States / cities
Alabaster, Alabama • Birmingham, Alabama • Tucson, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 2, 2026, 3:23 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis

NCT01016262
View directory record Official record
Conditions
Proctitis, Ulcerative
Interventions
MAX-002, Placebo, Canasa®
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 2, 2026, 3:23 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis

NCT02291523
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Fecal Microbial Transplant
Biological
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
7 Years to 21 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study

NCT01412372
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mesalamine, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 1 Interventional

Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

NCT01020708
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine, ALTH12-1:4, ALTH12-2:4
Drug
Lead sponsor
Altheus Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 4 Interventional Results available

Predicting Response to Standardized Pediatric Colitis Therapy

NCT01536535
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalazine, IV Corticosteroid, Oral Corticosteroids, Additional Therapies, Colectomy
Drug · Other · Procedure
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
4 Years to 17 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Hartford, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

Asacol Acute Diverticulitis(DIVA)Study

NCT00554099
View directory record Official record
Conditions
Diverticulitis
Interventions
Mesalamine, Probiotic, Placebo, Dietary Advice, Antibiotic for Diverticulitis
Drug · Other
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years to 85 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
36
States / cities
Tucson, Arizona • Los Angeles, California • Merced, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 1 Interventional

Effect of an Anti-Inflammatory Drug on Gut Mucosa in HIV Infected Patients

NCT00069498
View directory record Official record
Conditions
HIV Infections
Interventions
5-aminosalicylic acid
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 25, 2007 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Not applicable Interventional Results available

Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma

NCT01577966
View directory record Official record
Conditions
Brain Tumor
Interventions
Sulfasalazine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of Once a Day Dose Compared to 2 Doses/Day

NCT00505778
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalamine Once-Daily, Mesalamine Twice-Daily
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years and older
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
233
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis

NCT00269438
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
5 ASA, enemas, suppositories, corticosteroids
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers

NCT00622375
View directory record Official record
Conditions
Healthy
Interventions
mesalamine
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine

NCT01469637
View directory record Official record
Conditions
Healthy
Interventions
sulfamethoxazole + MMX placebo, Sulfamethoxazole + MMX Mesalazine/mesalamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)

NCT00577473
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 65 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
44
States / cities
Birmingham, Alabama • Anaheim, California • Sacramento, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers

NCT00751699
View directory record Official record
Conditions
Healthy
Interventions
Asacol, Lialda
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 3 Interventional

Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis

NCT00744016
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Granulated mesalamine, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bristol, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

Prevention of Recurrence of Diverticulitis

NCT00545103
View directory record Official record
Conditions
Diverticulitis
Interventions
SPD476, MMX™ mesalazine, 1.2g extended release tablet, SPD476, MMX™ mesalazine, 2.4g extended release tablet, SPD476, MMX™ mesalazine, 4.8g extended release tablet, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
59
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

NCT03399903
View directory record Official record
Conditions
HIV-1-infection, Gut Inflammation
Interventions
Pentasa vs Align
Drug
Lead sponsor
AIDS Healthcare Foundation
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 2, 2026, 3:23 PM EDT
Terminated Not applicable Interventional Results available

Safety and Compliance of Taking Mesalamine Once a Day in Pediatric Patients

NCT00349388
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol
Drug
Lead sponsor
Annette Langseder
Other
Eligibility
6 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls

NCT01860963
View directory record Official record
Conditions
Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA
Interventions
Anal Pap smear and HPV DNA testing
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 85 Years
Enrollment
310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 2, 2026, 3:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster

NCT03553472
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
35 Years to 49 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 2, 2026, 3:23 PM EDT